ANAB
AnaptysBio, Inc.·Healthcare
70.10
2.276%(+1.56)
Market ClosedLast Updated: — ET
52W L: $16.8252W H: $70.11
ANAB NEWS
defenseworld.net
Apr 3
AnaptysBio (NASDAQ:ANAB) Director John Schmid Sells 20,645 Shares of Stock
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) Director John Schmid sold 20,645 shares of the firm's stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $56.11, for a total value of $1,158,390.95. Following the completion of the transaction, the director owned 31,622 shares of the company's stock,
globenewswire.com
Mar 27
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has approved the previously announced spin-off of First Tracks Biotherapeutics, Inc. (“First Tracks Bio”). The new company is expected to begin “regular-way” trading on the Nasdaq Stock Market LLC (“Nasdaq”) on April 20, 2026, under the ticker symbol “TRAX.”
globenewswire.com
Mar 27
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the company may repurchase up to $100,000,000 of the company's outstanding common stock, par value $0.001 per share, and provided a business update.
globenewswire.com
Mar 27
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its planned spin-off, First Tracks Biotherapeutics, Inc. (“First Tracks Bio”), and EcoR1 Capital (the “Selling Stockholder”) have entered into a purchase agreement with certain third-party investors for a $145 million private placement, before deducting placement agent fees and other expenses.
seekingalpha.com
Mar 10
AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
defenseworld.net
Mar 8
AnaptysBio, Inc. $ANAB Shares Sold by Citigroup Inc.
Citigroup Inc. cut its position in shares of AnaptysBio, Inc. (NASDAQ: ANAB) by 93.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 70,534 shares of the biotechnology company's stock after selling 975,954 shares during the quarter. Citigroup Inc. owned 0.25% of
